SR-318
CAS No. 2413286-32-3
SR-318( —— )
Catalog No. M26463 CAS No. 2413286-32-3
SR-318 potently inhibits the TNF-α release in whole blood (IC50 = 283 nM). SR-318 is a potent and highly selective inhibitor of p38 MAPK. The IC50 values are 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 49 | Get Quote |
|
| 5MG | 80 | Get Quote |
|
| 10MG | 132 | Get Quote |
|
| 25MG | 267 | Get Quote |
|
| 50MG | 430 | Get Quote |
|
| 100MG | 620 | Get Quote |
|
| 500MG | 1332 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSR-318
-
NoteResearch use only, not for human use.
-
Brief DescriptionSR-318 potently inhibits the TNF-α release in whole blood (IC50 = 283 nM). SR-318 is a potent and highly selective inhibitor of p38 MAPK. The IC50 values are 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively.
-
DescriptionSR-318 potently inhibits the TNF-α release in whole blood (IC50 = 283 nM). SR-318 is a potent and highly selective inhibitor of p38 MAPK. The IC50 values are 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively.(In Vitro):SR-318 shows anti-cancer and anti-inflammatory activity. SR-318 can be used as a chemical probe for targeting this particular inactive state of these two p38 isoforms, p38α/β.
-
In VitroSR-318 presents a potent and selective type-II inhibitor of p38α/β that can be used as a chemical probe for targeting this particular inactive state of these two p38 isoforms.
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2413286-32-3
-
Formula Weight459.58
-
Molecular FormulaC27H33N5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (271.99 mM)
-
SMILESNc(n(-c1ccccc1)nc1)c1C(NCc(cc1)ccc1C(NCCCC1CCCCC1)=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Roux FA, Deschamps JY. Inadvertent intrathecal administration of ionic contrast medium to a dog. Vet Radiol Ultrasound. 2007 Sep-Oct;48(5):414-7. Review.
molnova catalog
related products
-
Losmapimod
Losmapimod (GSK-AHAB, GW856553X, SB856553)?is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.
-
Veraguensin
Veraguensin is derived from Magnolia sp.. Veraguensin inhibits bone resorption and shows high antileishmanial activity.
-
MW-150
MW-150 (MW01-18-150 SRM) is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM.
Cart
sales@molnova.com